Clinical Data Collection in Breast Tomosynthesis (COBRIS)
- Conditions
- Breast Cancer
- Interventions
- Device: Breast Tomosynthesis
- Registration Number
- NCT05914168
- Lead Sponsor
- GE Healthcare
- Brief Summary
The purpose of the study is to assess an image acquisition application for breast tomosynthesis in a clinical environment
- Detailed Description
After being informed about the study and potential risks, all patients giving written informed consent will undergo their routine mammography examination. One additional mammography view will be obtained with the investigational application and analyzed. Subject participation is expected to last no more than 30 minutes. After the mammography examination, subjects will be followed according to the hospital standard of care.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 150
- Women aged 35 years or older;
- Women referred for unilateral or bilateral 2D and 3D mammography;
- Women able and willing to comply with study procedures;
- Women able and willing to participate in this study who have signed and dated the informed consent form; and
- Women surgically sterile or postmenopausal or, the possibility of pregnancy is ruled out based on a negative urine pregnancy test
- Women who have been previously included in this study; or
- Be a minor, protected adult, adult deprived of liberty by judicial or administrative decision, pregnant, parturient or a breastfeeding mother; or
- Women with BRCA 1 or BRCA 2 gene mutation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Study arm Breast Tomosynthesis Subjects with investigational acquisition
- Primary Outcome Measures
Name Time Method Data Collection 1 year Collect clinical breast images obtained with the investigational application.
- Secondary Outcome Measures
Name Time Method Assessment of Image Quality 1 year Assess image quality through subjective and open expert evaluation of patient motion, visibility of replication artefacts and visibility of clinical findings.
Trial Locations
- Locations (1)
Gustave Roussy
🇫🇷Villejuif, France